Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1556751 | 1.00 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL5995010 | 0.83 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL9906339 | 0.83 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL1439353 | 0.83 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL1439357 | 0.83 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL31030763 | 0.77 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL4577847 | 0.74 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL4577849 | 0.74 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL6576126 | 0.73 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2POLBMAPT | |
| SCHEMBL13868568 | 0.71 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2021-04-29 | — | — | US | disclosed |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2020-03-12 | — | — | US | disclosed |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2018-12-06 | — | — | US | disclosed |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A ST CO LTD (KR) | 2017-11-23 | — | — | US | disclosed |
| US-8420676-B2 | Oxazolidinone derivatives | DONG-A PHARMACEUTICALS CO. LTD. (KR) | 2013-04-16 | — | — | US | disclosed |
| EP-2305657-B1 | Oxazolidinone derivatives | DONG A PHARM CO LTD (KR) | 2012-08-22 | — | — | EP | disclosed |
| EP-1699784-B1 | NOVEL OXAZOLIDINONE DERIVATIVES | DONG A PHARM CO LTD (KR) | 2011-06-29 | — | — | EP | disclosed |
| EP-2305657-A2 | Oxazolidinone derivatives | Dong-A Pharmaceutical Co., Ltd. (KR) | 2011-04-06 | — | — | EP | disclosed |
| US-7816379-B2 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2010-10-19 | — | — | US | disclosed |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | DONG-A PHARM. CO., LTD. (KR) | 2009-07-30 | — | — | US | disclosed |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | DONG-A PHARM. CO., LTD. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210121449-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | NPC1 2874/4885RAB9A 3975/4885SMN1; SMN2 4379/4885 |
| US-20070155798-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes torezolid phosphate | ALPI, SI, TST | NPC1 2486/4885RAB9A 3639/4885SMN1; SMN2 3702/4885 |
| US-20200078345-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | NPC1 2874/4885RAB9A 3975/4885SMN1; SMN2 4379/4885 |
| US-20090192197-A1 | Antibiotics with improved solubility, lower toxicity; potent antibacterial activity; includes Torezolid phosphate | ALPI, TPI1, SI | NPC1 2556/4885RAB9A 3377/4885SMN1; SMN2 4410/4885 |
| US-20170333414-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | NPC1 2874/4885RAB9A 3975/4885SMN1; SMN2 4379/4885 |
| US-20180344716-A1 | NOVEL OXAZOLIDINONE DERIVATIVES | ALPI, OXA1L, SI | NPC1 2874/4885RAB9A 3975/4885SMN1; SMN2 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.